GlassScriptPhysician profile
Irmela Salihovic
NPI 1013623289
$3,968.72
in general payments reported to CMS, 2019-2025
24 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,427 · 2024: $1,430 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,968.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $821.16 | 2023-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $584.29 | 2023-2025 | |
| Pfizer INC. | $513.06 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.13 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $251.28 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $231.48 | 2023-2025 | Verquvo |
| Novo Nordisk INC | $229.63 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $135.00 | 2024 | Voquezna |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.75 | 2023-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $103.95 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $103.41 | 2023-2025 | Farxiga, Andexxa |
| Amgen INC. | $78.44 | 2023-2024 | Repatha |
| Abbott Laboratories | $78.18 | 2024-2025 | Cardiomems, Assurity, Jot Dx |
| Janssen Pharmaceuticals, INC | $74.44 | 2023-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $63.60 | 2023-2024 | Uptravi, Opsumit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $54.99 | 2024 | Nexletol |
| United Therapeutics Corporation | $45.59 | 2023 | Tyvaso, Orenitram |
| Daiichi Sankyo INC. | $39.99 | 2023-2024 | Injectafer |
| Impulse Dynamics (USA) INC. | $32.55 | 2023-2024 | Optimizer, Optimizer |
| Bridgebio Pharma, INC. | $32.11 | 2025 | Attruby |
| Medtronic, INC. | $22.13 | 2024 | Corevalve Evolut R |
| Kiniksa Pharmaceuticals International, Plc | $19.55 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $18.53 | 2025 | |
| Boston Scientific Corporation | $14.48 | 2024 | Lux-Dx Insertable Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irmela Salihovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.